Thalys Medical Technology released its 2026 interim report, showing total operating revenue of 343 million yuan, down 41.26% year on year, and net profit attributable to the parent company of negative 47.8359 million yuan. Net cash flow from operating activities was negative 34.7836 million yuan, the asset-liability ratio was 35.49%, gross margin was 21.23%, return on equity was negative 4.38%, and diluted earnings per share was negative 0.22 yuan. The company had 63,600 shareholders, and the top ten shareholders held 23.09% of total share capital.
Wuhan Thalys Med Tech Co LtdReports net loss and sharp revenue decline in interim results.
